Short Interest in Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Declines By 86.8%

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 8,600 shares, a drop of 86.8% from the January 15th total of 65,100 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Antibe Therapeutics Stock Performance

Shares of ATBPF stock remained flat at $0.22 during trading on Wednesday. The stock has a 50-day moving average of $0.22 and a two-hundred day moving average of $0.22. Antibe Therapeutics has a 1-year low of $0.11 and a 1-year high of $0.89. The stock has a market capitalization of $11.42 million, a P/E ratio of -0.86 and a beta of 0.51.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).